Trial Profile
An international, multicenter, randomized, open-label, parallel efficacy, and safety trial of intravenous zoledronic acid compared to intravenous pamidronate in children with severe osteogenesis imperfect.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jun 2017
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Osteogenesis imperfecta
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals Corporation
- 14 Apr 2014 New trial record